Compare QCLS & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QCLS | CODX |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9M | 15.6M |
| IPO Year | N/A | 2017 |
| Metric | QCLS | CODX |
|---|---|---|
| Price | $4.45 | $0.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.25 |
| AVG Volume (30 Days) | ★ 10.2M | 1.6M |
| Earning Date | 11-19-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $507,892.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.50 | $0.23 |
| 52 Week High | $158.00 | $1.55 |
| Indicator | QCLS | CODX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 38.66 |
| Support Level | N/A | $0.34 |
| Resistance Level | N/A | $0.41 |
| Average True Range (ATR) | 0.00 | 0.04 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 0.28 |
Q/C Technologies Inc is engaged in building blockchain infrastructure that is faster and more energy-efficient. The company uses laser-based processors inspired by quantum technology that can solve complex problems at the speed of light. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.